IN8bio Presents Positive Phase 1 Data at TCT 2025, Highlighting Durability of Remissions in High-Risk AML
IN8bio is accelerating patient enrollment in the INB-100 program and expects to complete enrollment of the expansion cohort in 2025. The company’s FDA discussions confirmed that relapse-free survival ...
EQS-News: thyssenkrupp nucera Reports Strong Sales and EBIT Growth in First Quarter of New Fiscal Year
In the first quarter of the new reporting year, thyssenkrupp nucera continued to invest more in research and development with a focus on alkaline water electrolysis (AWE) and solid oxide electrolysis ...